Brown, Lisle/Cummings, Inc. Editas Medicine, Inc. Transaction History
Brown, Lisle/Cummings, Inc.
- $307 Billion
- Q2 2024
A detailed history of Brown, Lisle/Cummings, Inc. transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Brown, Lisle/Cummings, Inc. holds 65 shares of EDIT stock, worth $226. This represents 0.0% of its overall portfolio holdings.
Number of Shares
65Holding current value
$226% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding EDIT
# of Institutions
252Shares Held
58.7MCall Options Held
494KPut Options Held
417K-
Vanguard Group Inc Valley Forge, PA8.03MShares$28 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.78MShares$27.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$20.9 Million0.92% of portfolio
-
State Street Corp Boston, MA4.59MShares$16 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.46MShares$8.58 Million0.01% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $240M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...